There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regulus (RGLS – Research Report), Zevra Therapeutics (ZVRA – Research Report) and Clene (CLNN – Research Report) with bullish sentiments.
Regulus (RGLS)
In a report released yesterday, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Regulus, with a price target of $11.00. The company’s shares closed last Friday at $2.26.
According to TipRanks.com, Ijem is a 5-star analyst with an average return of
Currently, the analyst consensus on Regulus is a Strong Buy with an average price target of $7.67, representing a 260.1% upside. In a report issued on May 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $9.00 price target.
See the top stocks recommended by analysts >>
Clene (CLNN)
In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Clene, with a price target of $1.00. The company’s shares closed last Friday at $0.39, close to its 52-week low of $0.25.
According to TipRanks.com, Rahman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Clene is a Strong Buy with an average price target of $4.33, a 965.7% upside from current levels. In a report issued on May 8, H.C. Wainwright also maintained a Buy rating on the stock with a $7.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RGLS:
- Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
- Is RGLS a Buy, Before Earnings?
- Regulus’ Phase 1b trial of ADPKD candidate advances to Cohort 4
- Regulus files to sell 62.5M shares of common stock for holders
- Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
